Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
June 08 2023 - 3:19PM
Edgar (US Regulatory)
UNITEDSTATES
SECURITIESANDEXCHANGECOMMISSION
Washington,
D.C. 20549
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For
the month of May, 2023.
Commission
File Number: 000-51848
Avricore
Health Inc.
(Exact
name of registrant as specified in its charter)
1120-789
West Pender St, Vancouver, BC, V6C 1H2
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form
40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): NO
Note:
Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report
to security holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): NO
Note:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that
the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on
which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to
be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the
subject of a Form 6-K submission or other Commission filing on EDGAR.
Exhibits
The
following exhibits are included in this form 6-K:
| Exhibit
No. |
|
Description |
|
Date
Released |
| 1 |
|
Certification
of annual filings CEO for the year ended December 31, 2022 |
|
May
1, 2023 |
| 2 |
|
Certification
of annual filings CFO for the year ended December 31, 2022 |
|
May
1, 2023 |
| 3 |
|
AB
Form 13-501F1 (Class 1 and 3B Participation Fee) |
|
May
1, 2023 |
| 4 |
|
Audited
annual financial statements for the year ended December 31, 2022 |
|
May
1, 2023 |
| 5 |
|
MD&A
Annual filing for the year ended December 31, 2022 |
|
May
1, 2023 |
| 7 |
|
News
Release- AVRICORE GRANTS OPTIONS |
|
May
15, 2023 |
| 8 |
|
Form
of Proxy |
|
May
25, 2023 |
| 9 |
|
Management
information circular |
|
May
25, 2023 |
| 10 |
|
Notice
of meeting |
|
May
25, 2023 |
| 11 |
|
Financial
Statements request form |
|
May
25, 2023 |
| 12 |
|
Voting
instruction form |
|
May
25, 2023 |
| 13 |
|
Certification
of interim filings CEO for the period ended March 31-2023 |
|
May
31, 2023 |
| 14 |
|
Certification
of interim filings CFO for the period ended March 31-2023 |
|
May
31, 2023 |
| 15 |
|
Interim
financial statements/report for the period ended March 31-2023 |
|
May
31, 2023 |
| 16 |
|
MD&A
interim filing for the period ended March 31-2023 |
|
May
31, 2023 |
| 99.1 |
|
News Release- AVRICORE HEALTH CORPORATE UPDATES ON AUDITED RESULTS FOR 2022 |
|
May
2, 2023 |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| |
AVRICORE
HEALTH INC. |
| |
|
|
| Date:
June 08, 2023 |
By |
“Kiki
Smith” |
| |
|
Kiki
Smith |
| |
|
Chief
Financial Officer |
|
Persons
who are to respond to the collection of information contained |
| SEC1815(04-09) |
in
this form are
not required to
respond unless
the form
displays a
currently valid OMB
control number |
Avricore Health (QB) (USOTC:AVCRF)
Historical Stock Chart
From Nov 2024 to Dec 2024
Avricore Health (QB) (USOTC:AVCRF)
Historical Stock Chart
From Dec 2023 to Dec 2024
